Regeneron Pharmaceuticals (REGN) Competitors

Amgen (NASDAQ:AMGN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, community ranking, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Is AMGN or REGN more profitable?

Regeneron Pharmaceuticals has a net margin of 31.07% compared to Amgen's net margin of 12.24%. Amgen's return on equity of 176.32% beat Regeneron Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	12.24%	176.32%	11.71%
Regeneron Pharmaceuticals	31.07%	16.32%	12.76%

Does the MarketBeat Community prefer AMGN or REGN?

Regeneron Pharmaceuticals received 7 more outperform votes than Amgen when rated by MarketBeat users. However, 71.71% of users gave Amgen an outperform vote while only 66.95% of users gave Regeneron Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Amgen	Outperform Votes 1559 71.71%	Underperform Votes 615 28.29%
Regeneron Pharmaceuticals	Outperform Votes 1566 66.95%	Underperform Votes 773 33.05%

Which has better valuation and earnings, AMGN or REGN?

Regeneron Pharmaceuticals has lower revenue, but higher earnings than Amgen. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$34.13B	4.60	$4.09B	$10.96	26.63
Regeneron Pharmaceuticals	$14.09B	3.97	$4.41B	$39.28	13.20

Do insiders & institutionals have more ownership in AMGN or REGN?

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 0.8% of Amgen shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the media favor AMGN or REGN?

In the previous week, Amgen had 25 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 56 mentions for Amgen and 31 mentions for Regeneron Pharmaceuticals. Amgen's average media sentiment score of 1.32 beat Regeneron Pharmaceuticals' score of 0.71 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	45 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Regeneron Pharmaceuticals	19 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, AMGN or REGN?

Amgen has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500.

Is AMGN or REGN a better dividend stock?

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Regeneron Pharmaceuticals pays an annual dividend of $3.52 per share and has a dividend yield of 0.7%. Amgen pays out 86.9% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Regeneron Pharmaceuticals pays out 9.0% of its earnings in the form of a dividend. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Do analysts prefer AMGN or REGN?

Amgen presently has a consensus price target of $309.22, indicating a potential upside of 5.97%. Regeneron Pharmaceuticals has a consensus price target of $836.48, indicating a potential upside of 61.30%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	2 Sell rating(s)	12 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.38
Regeneron Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	2.85

Summary

Regeneron Pharmaceuticals beats Amgen on 12 of the 22 factors compared between the two stocks.